Annual report
6523.TEDINET S100W5A5
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥361.6bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥353.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥356.4bn | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥306.1bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥22.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥18.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥179m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥22.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥10.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥3.2bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥16.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥10.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥532.5bn | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥564.3bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥561.6bn | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥591.3bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥569.3bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥391.3bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥425.2bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥141.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥141.6bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥139.5bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥138.0bn | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥135.4bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥107.0bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥39.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥41.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥47.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥8.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥17.5bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥16.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥39.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.8bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥20.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥83.13 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-25.84 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥149.07 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥82.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-25.84 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥143.93 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,122.36 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,106.98 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,101.33 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,092.33 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥921.04 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 26.6% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.6% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 7.5% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -9.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -2.4% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -7.0% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 19.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 9,041 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 9,245 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 9,403 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 9,374 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 9,753 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥16.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥39.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥32.9bn | 2022-04-01 → 2023-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥39.2bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥8.8bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥8.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥30.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥23.3bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.7bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥11.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥7.9bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥16.4bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥19.3bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥132m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥431.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥467.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥457.3bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥467.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥432.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥332.4bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥372.3bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥98.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥94.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥96.7bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥96.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥50.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥10.2bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥11.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥62.39 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.25 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.96 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.62 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.17 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥62.13 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥129.59 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥153.15 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.08 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥42 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥38 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥778.8 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥751.98 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥759.31 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥763.79 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥428.12 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 22.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.4% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 126,410,072 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 126,244,271 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,522,074 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 124,144,242 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 114,831,084 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 176 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 141 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 151 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 175 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 181 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 288 pure |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥7.8bn |
| Diabetes Managementreportable segment | employees | at 2025-03-31 | 1425 pure |
| Diabetes Managementreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥98.7bn |
| Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥98.7bn |
| Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥13.9bn |
| Diagnostics And Life Sciencesreportable segment | employees | at 2025-03-31 | 3555 pure |
| Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥130.9bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥130.9bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Healthcare Solutionsreportable segment | employees | at 2025-03-31 | 3773 pure |
| Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥128.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥128.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥9.3bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥357.9bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥357.9bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥30.4bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥10.6bn |
| Diabetes Managementreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥101.6bn |
| Diabetes Managementreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥101.6bn |
| Diabetes Managementreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥16.0bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥129.7bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥129.7bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| Healthcare Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥120.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥120.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥9.4bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥351.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥351.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥12.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 176 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,961
| Item | Context | Value | Unit |
|---|---|---|---|
| Share option remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | － | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | － | JPY |
| Other remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideCorporateAuditorsMember | 2 | |
| Total amount of remuneration etc paid by group remuneration etc paid by group to each director or other officer | CurrentYearDuration_jpcrp030000-asr_E36976-000DeguchiKyokoMember | 150000000 | JPY |
| Number of issues shares not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant | 1 | |
| Carrying amount shares not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant | 1364000000 | JPY |
| Number of issues shares other than those not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant | － | |
| Carrying amount shares other than those not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant | － | JPY |
| Number of issues shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | － | |
| Carrying amount shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | － | JPY |
| Number of issues shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 1 | |
| Carrying amount shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 289000000 | JPY |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 2941176 | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | 2941176 | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 289000000 | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | 235000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 47044000000 | JPY |
| Cash and cash equivalents IFRS | CurrentYearInstant | 39592000000 | JPY |
| Trade receivables ca IFRS | Prior1YearInstant | 73802000000 | JPY |
| Trade receivables ca IFRS | CurrentYearInstant | 70530000000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 52651000000 | JPY |
| Inventories ca IFRS | CurrentYearInstant | 51694000000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 4775000000 | JPY |
| Other financial assets ca IFRS | CurrentYearInstant | 4308000000 | JPY |
| Other current assets ca IFRS | Prior1YearInstant | 9575000000 | JPY |
| Other current assets ca IFRS | CurrentYearInstant | 6665000000 | JPY |
| Current assets IFRS | Prior1YearInstant | 187849000000 | JPY |
| Current assets IFRS | CurrentYearInstant | 172790000000 | JPY |
| Property plant and equipment IFRS | Prior1YearInstant | 49708000000 | JPY |
| Property plant and equipment IFRS | CurrentYearInstant | 48374000000 | JPY |
| Goodwill IFRS | Prior1YearInstant | 208719000000 | JPY |
| Goodwill IFRS | CurrentYearInstant | 206500000000 | JPY |
| Intangible assets IFRS | Prior1YearInstant | 91388000000 | JPY |
| Intangible assets IFRS | CurrentYearInstant | 80649000000 | JPY |
| Investments accounted for using equity method IFRS | Prior1YearInstant | 2188000000 | JPY |
| Investments accounted for using equity method IFRS | CurrentYearInstant | 1821000000 | JPY |
| Other financial assets nca IFRS | Prior1YearInstant | 13987000000 | JPY |
| Other financial assets nca IFRS | CurrentYearInstant | 13932000000 | JPY |
| Deferred tax assets IFRS | Prior1YearInstant | 7058000000 | JPY |
| Deferred tax assets IFRS | CurrentYearInstant | 6120000000 | JPY |
| Other non current assets nca IFRS | Prior1YearInstant | 3426000000 | JPY |
| Other non current assets nca IFRS | CurrentYearInstant | 2293000000 | JPY |
| Non current assets IFRS | Prior1YearInstant | 376477000000 | JPY |
| Non current assets IFRS | CurrentYearInstant | 359691000000 | JPY |
| Assets IFRS | Prior1YearInstant | 564327000000 | JPY |
| Assets IFRS | CurrentYearInstant | 532482000000 | JPY |
| Trade and other payables cl IFRS | Prior1YearInstant | 69881000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |